Last updated: May 04, 2026

Application No. 18/282,507

ANTI-VACCINIA VIRUS ANTIGEN ANTIBODIES AND RELATED COMPOSITIONS AND METHODS

Non-Final OA

Filed

Sep 15, 2023

Priority

Mar 17, 2021 — provisional 63/162,199 +2 more

Examiner

HADDAD, MAHER M

Art Unit

1641

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

UVIC INDUSTRY PARTNERSHIPS INC.

OA Round

1 (Non-Final)

This examiner grants 50% of cases after interview

— +54.3% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 1044 resolved cases, 2023–2026

Examiner Intelligence

HADDAD, MAHER M View full profile →

Grants 50% of resolved cases

Career Allowance Rate

526 granted / 1044 resolved

-9.6% vs TC avg

Strong +54% interview lift

Without

With

+54.3%

Interview Lift

resolved cases with interview

Typical timeline

3y 0m

Avg Prosecution

53 currently pending

Career history

1097

Total Applications

across all art units

Statute-Specific Performance

§101

0.7%

-39.3% vs TC avg

§103

38.9%

-1.1% vs TC avg

§102

10.8%

-29.2% vs TC avg

§112

15.2%

-24.8% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1044 resolved cases

Prosecution Timeline

Sep 15, 2023

Application Filed

Mar 03, 2026

Non-Final Rejection (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/797,660

Patent 12613238

DIAGNOSTIC AND PROGNOSTIC UTILITY OF EXOSOMES IN IMMUNOTHERAPY

3y 8m to grant Granted Apr 28, 2026

17/923,462

Patent 12606613

HUMANIZED ANTI-C5A ANTIBODIES

3y 5m to grant Granted Apr 21, 2026

19/245,760

Patent 12606627

ALPHA4BETA7 INTEGRIN BINDING PROTEINS AND METHODS OF USE

10m to grant Granted Apr 21, 2026

19/065,094

Patent 12600770

ANTIBODIES TO CONNECTIVE TISSUE GROWTH FACTOR (CTGF) AND USES THEREOF

1y 1m to grant Granted Apr 14, 2026

18/015,690

Patent 12590166

CD20 BINDING MOLECULES AND USES THEREOF

3y 2m to grant Granted Mar 31, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

50%

Grant Probability

99%

With Interview (+54.3%)

3y 0m (~5m remaining)

Median Time to Grant

Low

PTA Risk

Based on 1044 resolved cases by this examiner. Grant probability derived from career allowance rate.